News from CRG
One of the CRG’s goals is to translate new scientific knowledge into benefits for health and value for society. To this end, the CRG Technology and Business Development Office has redefined its priorities and the way it brings innovative ideas to the market, launching several new programs and activities to promote commercialization and entrepreneurship. The latest change has been the reorganization of the CRG Business Board.
“We have increased our scouting and technology assessment activities and launched several initiatives to promote the spirit of innovation and entrepreneurship among CRG researchers, from training sessions, to seminars featuring grants or programmes promoting collaboration between scientists and entrepreneurs or companies. In this framework, we also wanted to reorganize the Business Board to make it more international and adapt it to the new CRG technology transfer strategy,” says Pablo Cironi, head of the Technology and Business Development Office at the Centre for Genomic Regulation.
The new CRG Business Board has six international members who are leading experts in entrepreneurship, business development, and technology transfer. In keeping with the new technology transfer strategy as well as the institute’s international profile, the board now includes private investors (from international venture capital firms and business angels) and experts from the fields of pharma, biotech and academia, all with solid experience in the life sciences and biotechnology sectors. The new members of the CRG Business Board are: Joël Jean-Mairet, General Partner at Ysios Capital Partners; Rudy Dekeyser, Partner at Life Science Partners; Michal Preminger, Executive Director and Director of Business Development at Harvard University; Jean-Jacques Degroof, Business Angel; Antonio Parente, President at GP-Pharm; and Clara Campàs, Strategy & Development Director at Kern Pharma s.l.